Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT00921193 Completed - Prostate Cancer Clinical Trials

Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer

Start date: May 2009
Phase: N/A
Study type: Interventional

The study aims to evaluate the safety and performance of the RTPS in patients with localized prostate cancer.The RTPS is an investigational device and requires permanent implantation of a small radioactive fiducial, called the Blip, in the prostate.

NCT ID: NCT00919477 Completed - Prostate Cancer Clinical Trials

Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg

CAMON
Start date: May 2009
Phase: N/A
Study type: Observational

To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).

NCT ID: NCT00919035 Completed - Prostate Cancer Clinical Trials

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Start date: June 2009
Phase: Phase 2
Study type: Interventional

This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.

NCT ID: NCT00918229 Completed - Prostate Cancer Clinical Trials

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

Start date: June 2009
Phase: N/A
Study type: Interventional

Primary Goal The study's primary goal is to assess the safety of the BioProtect biodegradable balloon implant and implantation procedure, in prostate cancer subjects undergoing routine radiation therapy (XRT) treatment. Safety of the BioProtect device will be assessed by reporting adverse events. Secondary Goal The study's secondary goal is to evaluate the effectiveness of the BioProtect biodegradable balloon implant in prostate cancer subjects undergoing routine XRT treatment. Effectiveness will be assessed in terms of increased distance between anterior rectal wall and prostate and noticeable reduction of isodose to the rectum.

NCT ID: NCT00917748 Completed - Breast Cancer Clinical Trials

Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The primary objective is: - To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: - To determine the effect of modafinil on quality of life (QoL) during docetaxel-based chemotherapy - To determine the effect of modafinil on patients physical activity level, functional status, number of chemotherapy cycles tolerated, sleep disturbance and depression, during docetaxel-based chemotherapy - To investigate the impact of tumour type, patient physical activity level, functional status, sleep disturbance and depression on the efficacy of modafinil at improving fatigue and quality of life during docetaxel-based chemotherapy. - To determine the safety and tolerability of modafinil during docetaxel-based chemotherapy

NCT ID: NCT00916123 Completed - Prostate Cancer Clinical Trials

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant prostate cancer.

NCT ID: NCT00913263 Completed - Prostate Cancer Clinical Trials

An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate

2-HOF
Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer. Primary efficacy variable was the proportion of patients showing PSA nadir. 24 Caucasian men, with a mean age at inclusion of 68.4 years, with localized prostate cancer were injected once with a ready made paste including 600 mg 2-hydroxyflutamide (Liproca Depot) into the site of the prostate where the tumour was localized. The patient was monitored for prostate-specific antigen (PSA) for maximum 6 months or to progression within this time period. The primary endpoint showed interesting results with high success rate (83%), i.e. proportion of patients (Responders) that reached plasma PSA nadir.

NCT ID: NCT00913068 Completed - Prostate Cancer Clinical Trials

Postoperative Pain Control for Prostatectomy

TAP
Start date: July 2009
Phase: N/A
Study type: Interventional

The researchers propose to investigate a relatively new anesthetic procedure, in order to maximize patient comfort and minimize the use of narcotics after a radical prostatectomy.

NCT ID: NCT00910754 Completed - Prostate Neoplasms Clinical Trials

A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of abiraterone acetate plus prednisone on the conduction of electric charges within the heart and to determine the blood levels of abiraterone acetate following administration in patients with metastatic castration-resistant prostate cancer.

NCT ID: NCT00908674 Completed - Prostate Cancer Clinical Trials

Androcur Effects on Quality of Life

Start date: June 2008
Phase: N/A
Study type: Observational

Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months